STRAtified Dosing based on Augmented renal clearance for CEFtriaxone in patients with severe community-acquired pneumonia: the STRADA-CEF trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502013-28-00

Enrollment

270

Registered

2023-12-11

Start date

2024-03-18

Completion date

Unknown

Last updated

2025-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Community-Acquired Pneumonia

Brief summary

Intensive care unit (ICU) Length of Stay (LOS)

Detailed description

Delta SOFA score, ICU mortality, 28-day mortality, Hospital LOS, Alive ICU free days at day 28, Ventilator-free days at day 28, Clinical cure at day 14, Microbial eradication at day 14, Emergence of resistance at day 14, PK/PD target attainment, Assessment of safety, Procalcitonin and C-reactive protein concentrations

Interventions

DRUGCEFTRIAXONE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Intensive care unit (ICU) Length of Stay (LOS)	—

Secondary

Measure	Time frame
Delta SOFA score, ICU mortality, 28-day mortality, Hospital LOS, Alive ICU free days at day 28, Ventilator-free days at day 28, Clinical cure at day 14, Microbial eradication at day 14, Emergence of resistance at day 14, PK/PD target attainment, Assessment of safety, Procalcitonin and C-reactive protein concentrations	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026